duralock 46,7% kateter lock otopina, duralock 30% kateter lock otopina i duralock-c 4% kateter lock otopina
tehmed d.o.o., pula - antikoagulacijska otopina za zatvaranje katetera
duralock-c 4 % otopina , 2x2,5ml, u špricama
tehmed d.o.o. tartinijeva 15 52100 pula -
duralock-c 46,7 % otopina , 2x2,5ml, u špricama
tehmed d.o.o. tartinijeva 15 52100 pula -
duraloc enduron and marathon liners
druŠtvo za proizvodnju, posredovanje i promet "urion" d.o.o. podgorica - neaktivna implantabilna medicinska sredstva
duraloc liner tip: marathon bantam enduron
druŠtvo za proizvodnju, posredovanje i promet "urion" d.o.o. podgorica - neaktivna implantabilna medicinska sredstva
neofen forte 400 mg/1 tableta filmom obložena tableta
farmavita d.o.o. sarajevo - ibuprofen - filmom obložena tableta - 400 mg/1 tableta - 1 filmom obložena tableta sadrži: 400 mg ibuprofena
fellefen 400 mg/1 tableta filmom obložena tableta
salvus bh d.o.o. - ibuprofen - filmom obložena tableta - 400 mg/1 tableta - 1 filmom obložena tableta sadrži: 400 mg ibuprofena
depuy implantati za kuk - protrusio cage, duraloc i pinnacle
johnson & johnson s.e. d.o.o., zagreb - zamjena za kuk
depuy implantati za kuk - duraloc, triloc, c-stem, elite plus, charnely, g2 i proxima
johnson & johnson s.e. d.o.o., zagreb - umjetni kuk
mhyosphere pcv id
laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - svinje - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.